Publications by authors named "K Treuner"
Purpose: Cancer of unknown primary (CUP) is a syndrome comprising metastatic cancers without a clinically identified primary site. Although patients with CUP have an unfavorable prognosis, treatment with site-specific therapies guided by clinical features, standard pathology, and molecular assays can improve overall survival. The 92-gene assay (CancerTYPE ID) is a gene expression-based classifier that helps identify the tissue of origin for metastatic cancers with unknown or uncertain diagnoses.
View Article and Find Full Text PDFImportance: Adjuvant ovarian function suppression (OFS) with oral endocrine therapy improves outcomes for premenopausal patients with hormone receptor-positive (HR+) breast cancer but adds adverse effects. A genomic biomarker for selecting patients most likely to benefit from OFS-based treatment is lacking.
Objective: To assess the predictive and prognostic performance of the Breast Cancer Index (BCI) for OFS benefit in premenopausal women with HR+ breast cancer.
Article Synopsis
- The Breast Cancer Index (BCI) assay helps assess late recurrence risk and inform decisions about extended endocrine therapy (EET) in early-stage breast cancer patients.
- Analysis of data from the BCI Registry showed significant changes in both physician recommendations and patient preferences regarding EET after BCI testing.
- Post-BCI testing, many patients felt more informed and confident about their treatment choices, with reduced concerns about costs and drug safety.
Article Synopsis
- The study examined the Breast Cancer Index (BCI) to predict benefits from extended endocrine therapy (EET) in hormone receptor-positive breast cancer patients participating in the NSABP B-42 trial.
- A total of 2,178 patients were analyzed, finding minimal overall RFI benefit from extended letrozole therapy, with no significant interaction between BCI levels and treatment outcome.
- However, after four years, patients with high BCI (H/I) showed significant benefits from EET, particularly in the HER2-negative subgroup, suggesting BCI's potential as a predictive marker for future studies.
Purpose: Patients with early-stage hormone receptor-positive (HR+) breast cancer face a prolonged risk of recurrence even after adjuvant endocrine therapy. The Breast Cancer Index (BCI) is significantly prognostic for overall (0-10 years) and late (5-10 years) distant recurrence (DR) risk in N0 and N1 patients. Here, BCI prognostic performance was evaluated in HR+ postmenopausal women from the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial.
View Article and Find Full Text PDF